H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Ultragenyx (RARE) to $50 from $60 and keeps a Buy rating on the shares. The firm cites reduced revenue growth expectations for the target cut. The company’s restructuring initiative to reduce costs and streamline operations could pave a path to profitability next year, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target lowered to $45 from $50 at Citi
- Ultragenyx Earnings Call Balances Growth With Risk
- Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures
- Ultragenyx price target lowered to $49 from $75 at TD Cowen
- Ultragenyx price target lowered to $61 from $71 at Goldman Sachs